Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Research Reports

China Oral Solid Dosage Pharmaceutical Formulation Market is expected to register a CAGR of 8.3% in the forecasted period 2022 to 2032

Oral Solid Dosage Pharmaceutical Formulation refers to the process of developing and manufacturing tablets, capsules, and other solid forms of medication that are intended to be ingested orally. Here’s a summary of the key aspects of oral solid dosage formulation:

NEWARK, Del: Demand for the global Oral Solid Dosage Pharmaceutical Formulation Market is anticipated to expand at a robust CAGR of 6.4% over the valuation period from 2022 to 2032. The global market is expected to touch US$ 555.3 Mn by 2022 and surpass a valuation of US$ 1.0 Bn in 2032. As per the studies, on the basis of dosage, the tablets segment led to the market with a massive share of around 53.1% in 2021.

As per Future Market Insights analysis, the oral solid dosage pharmaceutical formulation market accounted for around 1.4% of the overall US$ 40.0 Bn of the global pharmaceutical drug delivery market in 2021. The expansion of sales of solid dosage pharmaceutical formulations was anticipated at a robust rate of 8.1% from 2012 to 2021, attributed to the surging adoption and greater patient compliance.

Request a Sample Copy@

Oral solid dosages are one of the most commonly utilized pharmaceuticals that help in treating multiple chronic diseases. These oral solid dosages are witnessing high sales due to their cost-effective nature and are easily available in retail and hospital pharmacies across the globe. These dosage forms are easily manufactured and come with an affordable price point in numerous underdeveloped nations. This is expected to create lucrative growth prospects for the key players.

Key Takeaways

  • Since several research institutions and organizations are engaged in the drug discovery process, there is a massive amount of oral solid drugs in the process of approval with improved efficacy. Once these products are approved, the manufacturers are expected to be benefitted from generating profitable sales. Therefore, a positive impact due to the surging number of drug pipelines can be witnessed in the oral solid dosage pharmaceutical formulation market during the forecast period.
  • There is an overall surge witnessed in the demand for oral solid dosage drugs and vaccines for the treatment of various diseases and infections has also increased worldwide. Hence, prominent players in the market are working on developing drug manufacturing capacities of their own in low and medium-economy regions to capitalize on low production costs and availability of cost-effective raw materials.
  • Various firms practice the primary process of oral solid dosage pharmaceutical formulation. This is because the solid form of the drug is known to be the easiest and simplest way of administering a drug in order to have just the appropriate dose for various acute and chronic infections.
  • Such dosage forms offer advantages including chemical durability, stable transport, and safe packaging with low production costs. On the basis of region, Asia Pacific is expected to dominate the growth in the oral solid dosage pharmaceutical formulation market.
  • Tablets and capsules are utilized in pharmaceuticals to efficiently treat several disease conditions. In comparison to other pharmacological forms, these are cost-efficient and easy to manufacture. They offer several advantages such as easy transport and packaging and superior chemical and physical stability. Dominant market players are partnering with small and medium-sized manufacturers to produce low-cost and top-notch generic drugs maintained at a low cost of production in developing nations.

Request Customization@

Competitive Landscape

In the oral solid dosage pharmaceutical formulation market, dominant market players are adopting strategies such as mergers & acquisitions, and advanced product launches by gaining approvals. They are also collaborating with hospital and retail pharmacies to gain a competitive edge in the market.

Key Companies are AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc, Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, F. Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceuticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.

More Insights into the Oral Solid Dosage Pharmaceutical Formulation Market

The U.S. is expected to dominate the North American oral solid dosage pharmaceutical formulation market by accounting for a total market share of about 93.6% in 2021. Demand in the market is anticipated to grow due to the rising number of oral solid drug approvals in the country.

China is the second largest market in the East Asian region, as it accounted for around 51.4% of the total oral solid dosage pharmaceutical formulation market in 2021. Due to efficient drug production, key companies in China are offering medicines at cost-effective prices.

Germany is yet another market leading the European region as it is expected to grow at a CAGR of 6.7% during the forecast period. The growth of the oral solid dosage pharmaceutical formulation market is rising due to the prevalence of chronic diseases and heart diseases in Germany is aiding the demand for oral solid dosage forms.

Ask An Analyst@

Key Market Segments 

By Dosage Form:

  • Tablets
    • Conventional/Immediate Release
    • Modified Release
    • Chewable Tablets
    • Effervescent Tablets
  • Capsules
    • Hard Gelatin Capsules
    • Soft Gelatin Capsules
    • Others
  • Powders & Granules
  • Lozenges & Pastilles
  • Gummies

By Drug Release Mechanism:

  • Immediate Release
  • Delayed Release
  • Controlled Release

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Hypermarkets/Supermarkets

Get Full Access@

Table of Content

  1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply-Side Trends

1.4. Analysis and Recommendations

  1. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

  1. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Market Development/Innovation Trends

Get detailed TOC@

Explore FMI’s related ongoing Coverage on Healthcare Market Insights Domain

Brain Tumor Drugs Market Size: The brain tumor drugs market is estimated to record a 9.2% CAGR from 2023 to 2033. The market is likely to reach US$ 2.65 billion in 2023 and is expected to be worth US$ 6.30 billion in 2033.

Actinomycosis Market Opportunity: The actinomycosis market is anticipated to expand as society develops and looks for novel treatments for this ailment. In fact, it is expected that by 2033, global demand would be worth US$ 90 billion, growing at a CAGR of 6%.

Gene Therapy in CNS Disorder Market Demand: The global gene therapy in CNS disorder market is expected to garner a market value of US$ 8.2 Billion in 2023 and is expected to accumulate a market value of US$ 113.04 Billion by registering a CAGR of 30% in the forecast period 2023 to 2033.

Germ Cell Tumors Market Growth: As per Future Market Insights, the germ cell tumors market is anticipated to attain a value pool of US$ 10 billion by 2023-end. Global demand for germ cell tumor identification is expected to rise at a CAGR of 11.6% to US$ 30 billion in 2033.

Oncology Imaging Software Market Opportunity: The oncology imaging software market is on the rise and poised for tremendous growth, according to industry experts. The market is expected to reach a value pool of US$ 4 billion by the end of 2023, and demand is projected to rise at a CAGR of 5.8% to US$ 7 billion by 2033.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, U.S., and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

LinkedInTwitterBlogs | YouTube

For Sales Enquiries: [email protected]

Global Banking & Finance Review


Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!

By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review │ Banking │ Finance │ Technology. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post